Contrasting Pasithea Therapeutics (NASDAQ:KTTA) & Oncobiologics (NASDAQ:OTLK)

Pasithea Therapeutics (NASDAQ:KTTA) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Pasithea Therapeutics and Oncobiologics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1	0	1	1	2.67
Oncobiologics	1	4	2	0	2.14

Pasithea Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 524.35%. Oncobiologics has a consensus target price of $4.65, indicating a potential upside of 514.75%. Given Pasithea Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than Oncobiologics.

Profitability

This table compares Pasithea Therapeutics and Oncobiologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Oncobiologics	N/A	N/A	-291.28%

Institutional & Insider Ownership

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Pasithea Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Valuation and Earnings

This table compares Pasithea Therapeutics and Oncobiologics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43 million	($1.58)	-0.30
Oncobiologics	$1.35 million	83.25	-$62.42 million	($1.17)	-0.65

Pasithea Therapeutics has higher earnings, but lower revenue than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Pasithea Therapeutics beats Oncobiologics on 8 of the 13 factors compared between the two stocks.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.